Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients

被引：0

作者：

Paiva, Bruno ^{[1
]}

Mateos, Maria-Victoria ^{[2
]}

Ignacio Sanchez-Abarca, Luis ^{[3
]}

Belen Vidriales, Maria ^{[4
]}

Lopez-Corral, Lucia ^{[5
]}

Corchete, Luis A. ^{[5
]}

Hernandez, Miguel T. ^{[6
]}

Bargay, Joan ^{[7
]}

De Arriba, Felipe ^{[8
]}

De la Rubia, Javier ^{[9
]}

Isabel Teruel, Ana ^{[10
]}

Giraldo, Pilar ^{[11
]}

Rosinol, Laura ^{[12
]}

Prosper, Felipe ^{[13
]}

Oriol, Albert ^{[14
]}

Mariano Hernandez, Jose ^{[15
]}

Esteves, Graca ^{[16
]}

da Costa, Fernando Leal ^{[17
]}

Jose Lahuerta, Juan ^{[18
]}

Blade, Joan ^{[12
]}

Perez-Simon, Jose A. ^{[19
]}

San Miguel, Jesus ^{[20
]}

机构：

[1] Univ Navarra Clin, Dept Hematol & Immunol, Pamplona, Spain

[2] Univ Hosp Salamanca IBSAL, Dept Hematol, Salamanca, Spain

[3] IBSAL Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain

[4] Hosp Univ Salamanca, Dept Hematol, Salamanca, Spain

[5] Hosp Univ Salamanca, Salamanca, Spain

[6] Univ Hosp, Santa Cruz, CA USA

[7] Hosp Son Llatzer, Palma de Mallorca, Spain

[8] Hosp Univ Morales Meseguer, Ctr Reg Hemodonac, Hematol & Clin Oncol Unit, Murcia, Spain

[9] HUP La Fe, Valencia, Spain

[10] Hosp Clin Valencia, Valencia, Spain

[11] Minist Publ Hlth Russia, Hematol Res Ctr, Moscow, Russia

[12] Hosp Clin Barcelona, Barcelona, Spain

[13] Univ Navarra Clin, Pamplona, Spain

[14] Hosp Badalona Germans Trias & Pujol, lnst Catala Oncol, Barcelona, Spain

[15] Hosp Gen Segovia, Segovia, Spain

[16] Hosp Santa Maria, Lisbon, Portugal

[17] nst Portugues Oncol, Lisbon, Portugal

[18] Hosp 12 Octubre, E-28041 Madrid, Spain

[19] Hosp Univ Virgen Rocio, Dept Hematol, Seville, Spain

[20] Univ Navarra, Univ Navarra Clin, Ctr Invest Med Aplicada, E-31080 Pamplona, Spain

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma
Onishi, Yasushi
Yokoyama, Hisayuki
Katsuoka, Yuna
Ito, Toshihiro
Kimura, Tomohumi
Yamamoto, Joji
Nakajima, Shinji
Sasaki, Osamu
Ara, Takahide
Minauchi, Koichiro
Fukuhara, Osamu
Kobayashi, Naoki
Noji, Hideyoshi
Ota, Shuichi
Harigae, Hideo
ANNALS OF HEMATOLOGY, 2020, 99 (10) : 2351 - 2356
[42] Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma
Yasushi Onishi
Hisayuki Yokoyama
Yuna Katsuoka
Toshihiro Ito
Tomohumi Kimura
Joji Yamamoto
Shinji Nakajima
Osamu Sasaki
Takahide Ara
Koichiro Minauchi
Osamu Fukuhara
Naoki Kobayashi
Hideyoshi Noji
Shuichi Ota
Hideo Harigae
Annals of Hematology, 2020, 99 : 2351 - 2356
[43] Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study
Lonial, Sagar
Vij, Ravi
Harousseau, Jean-Luc
Facon, Thierry
Moreau, Philippe
Leleu, Xavier
Mazumder, Amitabha
Kaufman, Jonathan L.
Westland, Christopher E.
Tsao, Claire
Singhal, Anil K.
Jagannath, Sundar
BLOOD, 2010, 116 (21) : 805 - 806
[44] Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
Pierceall, William E.
Bahlis, Nizar
Siegel, David S.
Schiller, Gary J.
Samaras, Christy J.
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Srinivas, Shanti
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald P.
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Chung, Weiyuan
Serbina, Natalya
Zafar, Faiza
Agarwal, Amit
Thakurta, Anjan
BLOOD, 2018, 132
[45] Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone
Kalff, Anna
Khong, Tiffany
Ramachandran, Malarmathy
Norton, Sam
Mitchell, Andrew
Reynolds, John
Quach, Hang
Ho, P. Joy
Horvath, Noemi
Mollee, Peter
Kennedy, Nola
Kemp, Roslyn
Spencer, Andrew
BLOOD, 2019, 134
[46] A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
Patel, Roshani
Bhaskarla, Amrit
Gordon, Max J.
Emanuel, Michael
Colon, Dana I. Delgado
Wang, Hao-Wei
Yuan, Constance M.
Lindenberg, Liza
Mena, Esther
Turkbey, Baris
Micheletti, Nick
Yee, Laura M.
Patel, Nisha
Maric, Irina
Braylan, Raul C.
Calvo, Katherine R.
Staudt, Louis M.
Young, Ryan M.
Roschewski, Mark
Kazandjian, Dickran
Hill, Elizabeth
BLOOD, 2024, 144 : 7059 - 7060
[47] A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.
Reu, Frederic J.
Grabowski, Dale
Mahfouz, Reda Z.
Lazarus, Hillard M.
Dean, Robert M.
Faiman, Beth
Reed, Janice
Karam, Mary Ann
Hamilton, Kimberly
Fada, Sherry
Kalaycio, Matt E.
Valent, Jason Neil
Samaras, Christy Joy
Sobecks, Ronald M.
McCowen, Linda
Elberson, Jamie
Liu, Hien
Saunthararajah, Yogen
Chew, Yap
Smith, Mitchell R.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[48] OUTCOME OF ELDERLY PATIENTS 70 YEARS AND OLDER WITH NEWLY DIAGNOSED MYELOMA IN THE ECOG RANDOMIZED TRIAL OF LENALIDOMIDE/HIGH-DOSE DEXAMETHASONE (RD) VERSUS LENALIDOMIDE/LOW-DOSE DEXAMETHASONE (RD)
Jacobus, S.
Callander, N.
Siegel, D.
Abonour, R.
David, D.
Fonseca, R.
Williams, M.
Katz, M.
Greipp, P.
Rajkumar, V.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 149 - 149
[49] Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
Paiva, Bruno
Victoria Mateos, Maria
Ignacio Sanchez-Abarca, Luis
Puig, Noemi
Vidriales, Maria-Belen
Lopez-Corral, Lucia
Corchete, Luis A.
Hernandez, Miguel T.
Bargay, Joan
de Arriba, Felipe
de la Rubia, Javier
Teruel, Ana-Isabel
Giraldo, Pilar
Rosinol, Laura
Prosper, Felipe
Oriol, Albert
Hernandez, Jose
Esteves, Graca
Jose Lahuerta, Juan
Blade, Joan
Antonio Perez-Simon, Jose
San Miguel, Jesus F.
BLOOD, 2016, 127 (09) : 1151 - 1162
[50] ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
Ghobrial, Irene
Rodriguez-Otero, Paula
Koh, Youngil
Martinez-Lopez, Joaquin
Parmar, Gurdeep
Prince, Miles
Quach, Hang
de la Rubia, Javier
Hermansen, Emil
Hungria, Vania
Besisik, Sevgi Kalayoglu
Kim, Jin Seok
Leleu, Xavier
Peceliunas, Valdas
Schjesvold, Fredrik
Dubin, Franck
Devisme, Christine
Lepine, Lucie
Mace, Sandrine
Oprea, Corina
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S109 - S110

← 1 2 3 4 5 →